Lexaria Bioscience Corp. (LEXX) has released an update.
Lexaria Bioscience Corp. has embarked on its second human pilot study using its proprietary DehydraTECH technology to improve the oral delivery of GLP-1 drugs, which are traditionally hindered by poor absorption in the stomach. This groundbreaking study will test a new dissolvable oral tablet form against a control semaglutide tablet and a DehydraTECH capsule, potentially paving the way for a new era of non-injection-based diabetes treatment. The company aims to demonstrate the efficacy and safety of this novel oral dosage form which could eliminate the need for injections and reduce gastrointestinal discomfort.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
